



A versatile platform for efficient affinity optimization of common light chain bispecific antibodies

Jason Lajoie¹, Zach Frye¹, Alan Leung¹, Frano Irvine¹, Amanda Oliphant¹, Girish Hemashettar¹, Samantha Ottinger¹, Rachel McCrory¹, Dalton Markrush¹, Michael Schmidt¹

¹Compass Therapeutics, Cambridge, MA, USA


Abstract

Antibody constructs with the ability to bind multiple targets have the potential for a broad range of clinical applications that are not possible with monospecific IgG. However, given the complexities of mispairing of VH/VL during expression and purification, development of well-behaved bispecific antibodies often requires extensive protein engineering and process optimization efforts. To circumvent these issues, Compass Therapeutics has developed a fully integrated antibody discovery and optimization platform based on common light chains (cLC). Here we present our approach to lead affinity maturation with the goal of rapidly generating high affinity bispecifics. While other cLC optimization efforts introduce beneficial mutations only in the VH, we investigate both VH and cLC mutations in parallel. This increases the ability to rapidly achieve desired optimization goals in cases where VH-only approaches fall short.

VH optimization proceeds via introduction of combinatorial diversity in all three VH CDRs and isolation of high affinity clones via phage and/or mammalian display selections. cLC optimization presents more of a challenge as introduction of mutations which lead to enhanced affinity when paired with one VH partner may be deleterious for the other VH(s) in the final construct. To tackle this challenge, we employ parallel deep mutational scanning (DMS) of the cLC CDRs in combination with each component VH. Our DMS approach couples traditional library panning/sorting schemes with NGS to quantify the enrichment or depletion of every potential single amino acid mutation in the cLC CDRs. The DMS data from desired bispecific partners is then compared to identify compatible mutations which enhance or at least maintain the affinity when paired with each VH. These parallel affinity maturation approaches enable us to routinely generate single digit nM and sub-nM binding arms that can be directly combined in stable and manufacturable bispecifics with no further engineering required.

Compass Discovery Engine for IO Combinations


Efficient optimization of bispecific combinations needed to support rapid progression towards INDs




How can we achieve affinity optimization goals in a single round of screening while maintaining cLC?

Compass Affinity Maturation Platform

Single Round affinity maturation outputs



Affinity maturation workflow for common-LC bispecifics




Platform Highlights


- Ability to introduce mutations into the cLC
- Modular VH library components
- cLC Deep Mutational Scanning database under development
 - Storing, analyzing, and comparing NGS data for each cLC across campaigns
 - Anti-A can be paired/optimized with any other cLC clone
 - e.g. TAAxNkp30: Rapid optimization of novel combinations
- ≈2 months per campaign
- Ready-made cLC DMS libraries
- Library creation and screening is unbiased to final antibody format (mono-/bi-/multi-specific)
- Phage and/or human display

Modular VH and Ready-made cLC Libraries

Modular VH Library Construction





Ready-made cLC Libraries



DMS-guided light chain design

Enrichment Ratio data analysis used to design compatible cLCs



DMS data predicts binding affinity behavior

Heavy Chain	Light Chain	K _D (M)	Fold Change
Anti-A WT VH	cLC	4.0E-07	WT
Anti-B WT VH	cLC	1.5E-07	WT
Anti-A AffMat VH	cLC	2.0E-08	20
Anti-B AffMat VH	cLC	9.2E-09	16
Anti-A AffMat VH	S91G	7.5E-10	539
Anti-B AffMat VH	S91G	NB	-
Anti-A AffMat VH	Y49K	1.8E-09	222
Anti-B AffMat VH	Y49K	NB	-
Anti-A AffMat VH	A50Q	3.4E-07	1
Anti-B AffMat VH	A50Q	7.0E-10	216
Anti-A AffMat VH	S30N	2.4E-09	167
Anti-B AffMat VH	S30N	4.9E-09	31
Anti-A AffMat VH	S30N, T94I	1.7E-09	235
Anti-B AffMat VH	S30N, T94I	1.9E-09	81

VH Optimization yielded significant affinity improvement


cLC DMS data predicted incompatible mutations

cLC DMS data predicted compatible mutations


Successful affinity optimization against both targets in a single round!

DMS for efficient monoclonal engineering

Enrichment Ratio data analysis used to design improved LC



500-fold affinity improvement in a single round




Discussion


- Including cLC DMS analysis in every affinity maturation campaign allows optimization to proceed without bias to final antibody format
- DMS-guided design of optimized LCs enables rapid affinity improvements without additional rounds of library generation and sorting

Bispecific optimization via HEK display of cLC libraries

cLC combinatorial library design and HEK bispecific display



Library sorting to isolate high affinity dual binding clones



Bispecific display library sorting and analysis

- Analytical flow plots demonstrate the presence of high affinity dual binding clones in the library which outperform the WT cLC after off-rate competition
- The dual binding population will be sorted, sequenced, and characterized to identify dual affinity improving mutations in the cLC

Conclusions and Future Directions

- We developed and implemented a rapid and efficient platform for affinity optimization of cLC bispecific antibodies
- cLC DMS analysis is included in every affinity maturation campaign:
 - Optimization proceeds without bias to final antibody format
 - cLC compatibility is maintained for any combination of lead antibodies
 - Affinity improvement goals achieved in a single round of mutagenesis and screening
 - ≈2 months/campaign
 - Proprietary HEK bispecific display coupled with DMS-guided library design enables high throughput identification of optimal cLCs when additional fine tuning is necessary
- Further development and validation of cLC database to store and analyze data across campaigns:
 - Integration of NGS, binding, stability, structural data etc.
 - Implementation of lessons learned from the database for better in silico antibody design